Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tax1-binding protein 3 (TAX1BP3) is a small, highly conserved human protein consisting mainly of a single PDZ domain. Originally discovered for its interaction with the Tax oncoprotein of human T-cell leukemia virus type I (HTLV-1), it differs from other PDZ proteins by lacking multiple domains, suggesting it may act to inhibit or disrupt protein–protein interactions, notably in cytosolic signaling. TAX1BP3 regulates cell signaling, adhesion, migration, stress response, and polarization via interactions with various proteins (such as Rho A, glutaminase L, beta-catenin, and ion channels). Mechanistically, it inhibits the Wnt/beta-catenin pathway, modulates cell surface protein localization, and participates in the regulation of Cdc42 and Rho pathways. TAX1BP3 is broadly expressed, including in nervous, bone, and cancerous tissues, and its overexpression is associated with altered cell behavior in cancer, developmental diseases, and bone differentiation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tax1-binding protein 3 (TAX1BP3).